Clinical Trial Update: PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD) [Phase 1]

View source ↗

Summary

Phase 1 study PRECISE-AD evaluating PMN310 for early-onset Alzheimer disease is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• PMN310

Snippet

Sponsor: ProMis Neurosciences, Inc | Conditions: Alzheimer Disease, Early Onset | Phase 1 | Status: ACTIVE_NOT_RECRUITING